We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

CRISPR and Genome Editing – News and Features

News

Lexicon Granted License to Cellectis' Homologous Recombination Technology

Lexicon uses the technology in generating genetically-engineered mice in combination with IRES or isogenic DNA technology.
News

Researchers Discover way to Develop T-cells From Human Embryonic Stem Cells

Study raises hopes for a gene therapy to combat AIDS.
News

Future Medicine Launches 'Nanomedicine' Journal

Nanomedicine will cover the emerging scientific specialty born from nanotechnology.
News

"Land of the Ever-Young" Gene Reprogrammes Cells

A team of scientists at the Institute for Stem Cell Research investigated the switching of adult cell types into embryonic stem cells after cell fusion.
News

Developments Improve Safety of Stem Cell Transplantation in the Treatment of Leukaemia

Study shows that a 'suicide' gene can be used to cut short rejection reactions following stem cell transplants.
News

Stem Cell Pioneers Confirm Patents Pending for two Advances in the Efficiency of Cloning Stem Cells

Gene "Nanog" play a dominant role in reprogramming tissue cells into an embryonic stem cell state without the need for generating an embryo.
News

Cyntellect Receives $2.2 Million Milestone Payment From Sigma-Aldrich

The milestone payment represents Cyntellect's satisfaction of certain terms and conditions under the Cell Xpress™ service commercialization agreement.
News

Dharmacon and Amaxa Collaborate to Improve siRNA Delivery into Cells

Amaxa's Nucleofector® technology enables siRNA transfer into primary cells and non-standard cell lines.
News

Inovio at ASGT 9th Annual Meeting

Inovio’s presentation showcase potential for electroporation in delivering DNA vaccines.
News

Moffitt and Inovio Announce Positive Results from Human Study of Plasmid DNA Delivery Using Electroporation

Collaborators encouraged by interim data from phase I clinical study of patients with malignant melanoma.
Advertisement